The host immune dynamics of pneumococcal colonization: implications for novel vaccine development
- PMID: 25668673
- PMCID: PMC4514076
- DOI: 10.4161/21645515.2014.979631
The host immune dynamics of pneumococcal colonization: implications for novel vaccine development
Abstract
The human nasopharynx (NP) microbiota is complex and diverse and Streptococcus pneumoniae (pneumococcus) is a frequent member. In the first few years of life, children experience maturation of their immune system thereby conferring homeostatic balance in which pneumococci are typically rendered as harmless colonizers in the upper respiratory environment. Pneumococcal carriage declines in many children before they acquire capsular-specific antibodies, suggesting a capsule antibody-independent mechanism of natural protection against pneumococcal carriage in early childhood. A child's immune system in the first few years of life is Th2-skewed so as to avoid inflammation-induced immunopathology. Understanding Th1/Th2 and Th17 ontogeny in early life and how adjuvant vaccine formulations shift the balance of T helper-cell differentiation, may facilitate the development of new protein-based pneumococcal vaccines. This article will discuss the immune dynamics of pneumococcal colonization in infants. The discussion aims to benefit the design and improvement of protein subunit-based next-generation pneumococcal vaccines.
Keywords: IPDs, invasive pneumococcal diseases; MHC, major histocompatibility complex; NP, nasopharynx; OPAs, opsonophagocytic antibodies; PPS, pneumococcal polysaccharides; PPVs, pneumococcal polysaccharide vaccines; PcpA, pneumococcal choline-binding protein A; Streptococcus pneumoniae; T cells; WCV, whole cell vaccine; colonization; immunity; vaccines.
Figures
References
-
- Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, Lexau CA, Thomas AR, Harrison LH, Reingold AL, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. Jama 2006; 295:1668-74; PMID:16609088; http://dx.doi.org/ 10.1001/jama.295.14.1668 - DOI - PubMed
-
- Lee H, Choi EH, Lee HJ. Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines. Korean J Pediatr 2014; 57:55-66; PMID:24678328; http://dx.doi.org/ 10.3345/kjp.2014.57.2.55 - DOI - PMC - PubMed
-
- Principi N, Esposito S. Use of the 13-valent pneumococcal conjugate vaccine in infants and young children. Expert Opin Biol Ther 2012; 12:641-8; PMID:22397739; http://dx.doi.org/ 10.1517/14712598.2012.670217 - DOI - PubMed
-
- Ruckinger S, van der Linden M, Siedler A, von Kries R. Potential benefits from currently available three pneumococcal vaccines for children–population-based evaluation. Klin Padiatr 2011; 223:61-4; PMID:21271500; http://dx.doi.org/ 10.1055/s-0030-1268465 - DOI - PubMed
-
- Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007; 25:2194-212; PMID:17267077; http://dx.doi.org/ 10.1016/j.vaccine.2006.11.032 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous